Working… Menu

Anesthetics and Analgesics in Children (ANA01)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03427736
Recruitment Status : Recruiting
First Posted : February 9, 2018
Last Update Posted : November 13, 2020
The Emmes Company, LLC
Information provided by (Responsible Party):
Kanecia Zimmerman, MD MPH, Duke University

Brief Summary:
The purpose of this study is to characterize the pharmacokinetic (PK) and safety profile of anesthetics and analgesics in children and adolescents.

Condition or disease Intervention/treatment
Anesthesia Pain Drug: Ketorolac Tromethamine Drug: Hydromorphone

Detailed Description:
This is a research study to find out what the side effects are of certain drugs that are commonly used for pain and to put people to sleep for surgery. The researchers also want to know how the drug is broken down in the body. Participants will be given these drugs as they are prescribed by their regular doctor. As part of the participant's standard of care, doctors will perform tests, ask questions, review medical information and measure vital signs (heart rate, blood pressure, etc). The researchers will collect information that doctors have already written in the medical records. The research study team will collect blood from participants at certain time points depending on when the participant was first given the drug (up to 5 samples over the course of 10 to 48 hours). Parents will complete questionnaires about the study participant. Parents will continue to complete those same questionnaires for up to 12 months after the participant was first given the drug. Examples of current and upcoming anesthetics and analgesics include, but are not limited to: hydromorphone (Dilaudid), ketorolac (Toradol), methadone and ketamine.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 120 participants
Observational Model: Other
Time Perspective: Prospective
Official Title: Pharmacokinetics of Anesthetics and Analgesics in Children and Adolescent
Actual Study Start Date : December 13, 2018
Estimated Primary Completion Date : June 2022
Estimated Study Completion Date : June 2023

Resource links provided by the National Library of Medicine

Group/Cohort Intervention/treatment
Drug of Interest
Individuals receiving anesthetics or analgesics per standard of care
Drug: Ketorolac Tromethamine
IV ketorolac will be given per standard of care, not prescribed for this study
Other Name: Toradol

Drug: Hydromorphone
IV Hydromorphone will be given per standard of care, not prescribed for this study
Other Names:
  • Hydromorphone hydrochloride
  • Dilaudid

Primary Outcome Measures :
  1. Clearance (CL) or apparent oral clearance (CL/F) [ Time Frame: up to 48 hours post dose ]
  2. Volume of distribution (V) or apparent oral volume of distribution (V/F) [ Time Frame: up to 48 hours post dose ]
  3. Elimination rate constant (ke) [ Time Frame: up to 48 hrs post dose ]
  4. Half-life (t1/2) [ Time Frame: up to 48 hrs post dose ]
  5. Absorption rate constant (ka) [ Time Frame: up to 48 hrs post dose ]
  6. Area under the curve (AUC) [ Time Frame: up to 48 hrs post dose ]
  7. Maximum concentration (CMAX) [ Time Frame: up to 48 hrs post dose ]
  8. Time to achieve maximum concentration (TMAX) [ Time Frame: up to 48 hrs post dose ]

Biospecimen Retention:   Samples With DNA
Left over specimens may be sent to the NICHD biorepository at the consent of the study participant. This is optional. But future unspecified tests conducted may include genetic testing.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   2 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Approximately 60 participants will be enrolled to each of the study drug of interests (DOI) cohorts. Participants who satisfy eligibility criteria and are receiving one or more DOIs per standard of care will be consented into the study and assigned to the corresponding DOI cohort. DOI cohort assignments will be at the discretion of the treating physician based on the DOIs that are administered per standard of care. Participants will be selected from a variety of centers including but not limited to trauma and intensive care units. Participants will not be randomized. Participants may count towards 1 or more DOIs within the same 90-day period.

Inclusion Criteria:

  • 2 years to < 18 years at the time of enrollment
  • Parent is able to understand the consent process and provides informed consent/HIPAA
  • Participant provides assent and as required by the institutional review board
  • Receiving one or more drugs of interest (DOI) per local standard of care meeting DOI-specific inclusion criteria

Exclusion Criteria:

  • Known pregnancy
  • Extracorporeal life support (i.e., Extracorporeal membrane oxygenation, dialysis, ventricular assist device)
  • Any condition which would make the participant, in the opinion of the investigator, unsuitable for the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03427736

Layout table for location contacts
Contact: Christie Milleson 919-668-6055
Contact: Phyllis Kennel 919-668-9958

Layout table for location information
United States, California
University of California San Francisco Recruiting
San Francisco, California, United States, 94143
Contact: Scott Schulman, MD    415-502-4222   
Contact: Anne Mckenzie    1-415-476-3758   
Lucile Packard Children's Hospital Recruiting
Stanford, California, United States, 94305
Contact: Alexandria George    650-232-9152   
Contact: Elie Abinader    1-650-339-9685   
United States, Colorado
Children's Hospital Colorado Recruiting
Aurora, Colorado, United States, 80045
Contact: Peter Mourani, MD    303-724-2390   
Contact: Kevin Van    720-777-2808   
United States, Delaware
Alfred I. DuPont Hospital for Children Recruiting
Wilmington, Delaware, United States, 19803
Contact: Marisa Meyer, MD    302-651-4021   
Contact: Ramany John    1-302-298-7521   
United States, Missouri
Cardinal Glennon Children's Hospital Recruiting
Saint Louis, Missouri, United States, 63104
Contact: Stephanie Taylor    417-880-3424   
Contact: Erik Madsen, MD    314-577-1590   
Washington University School of Medicine Recruiting
Saint Louis, Missouri, United States, 63110
Contact: Mike Montana, MD, PhD    314-565-8119   
Contact: Alan Hifko    314-273-0873   
United States, New Mexico
University of New Mexico, Health Sciences Center Recruiting
Albuquerque, New Mexico, United States, 87131
Contact: Olivia Nunez    505-272-9898   
Contact: Hengameh Raissy    1-505-272-8240   
United States, North Carolina
Duke University Medical Center Recruiting
Durham, North Carolina, United States, 27701
Contact: Melissa Harward    919-668-3910   
Contact: Chi Hornik    919.970.6680   
United States, Oregon
Oregon Health and Science University Recruiting
Portland, Oregon, United States, 97239
Contact: Kimberly Grzesek    503-494-2797   
Contact: Sarah Craven    1-503-418-6676   
United States, South Carolina
Medical University of South Carolina Recruiting
Charleston, South Carolina, United States, 29425
Contact: John Costello, MD    843-792-9570   
Contact: Mary Freeman    843-792-5762   
United States, Tennessee
Vanderbilt University Active, not recruiting
Nashville, Tennessee, United States, 37232
United States, Texas
Baylor College of Medicine Recruiting
Houston, Texas, United States, 77030
Contact: Dean Andropoulos    832-826-5832   
Contact: Margaret Owens-Stuberfield    832-824-5913   
University of Texas Health Science Center Recruiting
Houston, Texas, United States, 77030
Contact: Jon Meliones    713-500-5359   
Contact: Nutan Hebballi    713-500-7010   
Canada, Ontario
The Hospital for Sick Children Not yet recruiting
Toronto, Ontario, Canada, M5G 1X8
Contact: Yaron Finkelstein    416-813-5317   
Contact: Maggie Rumantir    416-813-7654   
Canada, Quebec
Hospital Sainte-Justine Not yet recruiting
Montreal, Quebec, Canada, T3T 1C5
Contact: Julie Autmizguine    514-345-4931   
Contact: Mary-Ellen French    514-345-4931   
Sponsors and Collaborators
Kanecia Zimmerman, MD MPH
The Emmes Company, LLC
Layout table for investigator information
Principal Investigator: Kanecia Zimmerman Duke Clinical Research Institute
Layout table for additonal information
Responsible Party: Kanecia Zimmerman, MD MPH, Assistant Professor of Pediatrics, Duke University Identifier: NCT03427736    
Other Study ID Numbers: Pro00088893
First Posted: February 9, 2018    Key Record Dates
Last Update Posted: November 13, 2020
Last Verified: November 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: All data collected is uploaded into the National Institute of Health data repository (DASH) at the end of the study (de-identified).
Time Frame: Data will be uploaded to the repository within 2 years of study completion. It will be maintained in the repository indefinitely.
Access Criteria:

In order to have access, researchers have to complete a Data access request. NICHD will review the request and either approve or deny it. IRB approval must be obtained by the researcher to access the data.


Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Ketorolac Tromethamine
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Analgesics, Opioid
Central Nervous System Depressants